Solid tumor/s, Cancer, Non-small cell lung carcinoma
BNTXBioNTech SECatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for BNT116 +/- cemiplimab in Solid tumor/s, Cancer, Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
W/ Regeneron. EMPOWERVAX Lung 1 trial. Presentation at ESMO '23. 08/20/26:- Preliminary neoadjuvant Ph1 results to present at WCLC Sep 14, 2026.
Verification
Confirm timing and program details against the company announcement or filing.